EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access · CC BY 4.0

Quadrivalent HPV (4vHPV) vaccine immunogenicity and safety in women using immunosuppressive drugs due to solid organ transplant

Karina Takesaki Miyaji, Vanessa Infante, Camila Melo Picone, Joakim Dillner, Hanna Kann, Carina Eklund, José Eduardo Levi, Ana Carolina Soares de Oliveira, Amanda Nazareth Lara, Lyca Suzuki Kawakami, Maricy Tacla, Cristina Paula Castanheira und 2 weitere

Frontiers in Cellular and Infection Microbiology · 2024

DOI: 10.3389/fcimb.2024.1452916 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2024. Verfasst von Karina Takesaki Miyaji und 13 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Infectologia e Medicina Tropical da Faculdade de Medicina da Universidade de Sao Paulo (FMUSP), Sao Paulo, Brazil. Hauptthemen laut MEDLINE: Antibodies, Viral, Papillomavirus Infections, Immunosuppressive Agents, Organ Transplantation. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Immunocompromised persons are at high risk of persistent Human Papilloma Virus (HPV) infection and associated diseases. Few studies evaluated HPV vaccines in immunocompromised persons. This study aimed to evaluate the quadrivalent HPV vaccine (4vHPV) immunogenicity and safety in solid organ transplant (SOT) recipients, in comparison to immunocompetent women (IC).

Methods

Open-label clinical trial that enrolled SOT recipients and immunocompetent women aged 18 to 45 years. All participants received three doses of 4vHPV vaccine. Blood samples were drawn for evaluation of immune responses at baseline and one month after the third vaccination. Seroconversion rates and antibody geometric mean concentration (GMC) against HPV 6, 11, 16, 18, 31, 35, 52 and 58 were measured with in-house multiplexed serology assay (xMAP technology). Follow-up for the local and systemic adverse events (AEs) continued for seven days after each vaccination. Severe AEs were evaluated throughout the study.

Results

125 SOT and 132 immunocompetent women were enrolled; 105 (84%) SOT and 119 (90%) immunocompetent women completed the study. At baseline, HPV seropositivity was not significantly different between groups. Seroconversion rates were significantly lower in SOT (HPV18, 57%; HPV6 and 16, 69%; and HPV11, 72%) than in immunocompetent women (100% seroconversion to all vaccine types) ( p <0.001). Antibody GMCs of all four HPV vaccine types were also significantly lower in SOT ( p <0.001). Pain in the injection site and headache were the most frequent adverse event in both groups. Local pain was more frequent in immunocompetent women than in SOT recipients. Rates of other AEs were comparable in both groups.

Conclusion

4vHPV vaccine was well-tolerated by SOT recipients. We found strong evidence of lower humoral immune responses to 4vHPV vaccine in SOT compared to immunocompetent women, which strengthen recommendation of routine cervical cancer screening in SOT recipients regardless of HPV vaccination status.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, ViralPapillomavirus InfectionsImmunosuppressive AgentsOrgan TransplantationImmunogenicity, VaccineHumansFemaleAdultYoung AdultMiddle AgedAdolescentPapillomavirus VaccinesImmunocompromised HostHuman Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18Transplant RecipientsSeroconversionVaccination

Stichwörter der Autor:innen

cancer preventionimmunogenicityimmunosuppressionpapillomavirus vaccinessafetysolid organ transplant

Substanzen

Antibodies, ViralImmunosuppressive AgentsPapillomavirus VaccinesHuman Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18

Autor:innen und Institutionen

  • Departamento de Infectologia e Medicina Tropical da Faculdade de Medicina da Universidade de Sao Paulo (FMUSP), Sao Paulo, Brazil.
  • Clinica de Molestias Infecciosas e Parasitarias do Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil.
  • Centro de Referencia para Imunobiológicos Especiais, HCFMUSP, Sao Paulo, Brazil.
  • Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden.
  • Department of Microbiology and Immunology, Gothenburg University, Gothenburg, Sweden.
  • Laboratório de Investigação Medica - Virologia, Instituto de Medicina Tropical, Sao Paulo, Brazil.

Zitieren

APA

Miyaji, K. T., Infante, V., Picone, C. M., Dillner, J., Kann, H., Eklund, C., Levi, J. E., de Oliveira, A. C. S., Lara, A. N., Kawakami, L. S., Tacla, M., Castanheira, C. P., Mayaud, P., & Sartori, A. M. C. (2024). Quadrivalent HPV (4vHPV) vaccine immunogenicity and safety in women using immunosuppressive drugs due to solid organ transplant. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2024.1452916

Vancouver

Miyaji KT, Infante V, Picone CM, Dillner J, Kann H, Eklund C, et al. Quadrivalent HPV (4vHPV) vaccine immunogenicity and safety in women using immunosuppressive drugs due to solid organ transplant. Frontiers in Cellular and Infection Microbiology. 2024. doi:10.3389/fcimb.2024.1452916

BibTeX
@article{Miyaji2024,
  author = {Miyaji, Karina Takesaki and Infante, Vanessa and Picone, Camila Melo and Dillner, Joakim and Kann, Hanna and Eklund, Carina and Levi, José Eduardo and de Oliveira, Ana Carolina Soares and Lara, Amanda Nazareth and Kawakami, Lyca Suzuki and Tacla, Maricy and Castanheira, Cristina Paula and Mayaud, Philippe and Sartori, Ana Marli Christovam},
  title = {Quadrivalent HPV (4vHPV) vaccine immunogenicity and safety in women using immunosuppressive drugs due to solid organ transplant},
  journal = {Frontiers in Cellular and Infection Microbiology},
  year = {2024},
  doi = {10.3389/fcimb.2024.1452916}
}
Kostenlos starten →